JO3382B1 - أجسام مضادة ترتبط مع مستقبل cgrp بشري - Google Patents
أجسام مضادة ترتبط مع مستقبل cgrp بشريInfo
- Publication number
- JO3382B1 JO3382B1 JOP/2009/0461A JOP20090461A JO3382B1 JO 3382 B1 JO3382 B1 JO 3382B1 JO P20090461 A JOP20090461 A JO P20090461A JO 3382 B1 JO3382 B1 JO 3382B1
- Authority
- JO
- Jordan
- Prior art keywords
- cgrp
- receptor binding
- cgrp receptor
- binding antibodies
- human cgrp
- Prior art date
Links
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 title abstract 2
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 title abstract 2
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 abstract 4
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 abstract 4
- 102000025171 antigen binding proteins Human genes 0.000 abstract 3
- 108091000831 antigen binding proteins Proteins 0.000 abstract 3
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 206010027603 Migraine headaches Diseases 0.000 abstract 1
- DNKYDHSONDSTNJ-XJVRLEFXSA-N chembl1910953 Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)N)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CN=CN1 DNKYDHSONDSTNJ-XJVRLEFXSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
Abstract
تقدم بروتينات مستضد الرابطة التي تربط بمستقبل جين كالسيتونين المرتبط بالبتيد CGRPR . كما تم توفير حموض نووية التي تشفر بروتين الرابطة للمستضد، ناقلات والخلايا التي تشفرها. يمكن تثبيط تشفير بروتين الرابطة للمستضد الرابط لمستقبل جين كالسيتونين المرتبط بالبتيد الى جين كالسيتونين المرتبط بالبتيد والتي تكون مفيدة في رقم مستقبل جين كالسيتونين المرتبط بالبتيد للاضطرابات المتعلقة، بما في ذلك معالجة و/او وقاية الصداع الشقي.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20356908P | 2008-12-23 | 2008-12-23 | |
US26462209P | 2009-11-25 | 2009-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
JO3382B1 true JO3382B1 (ar) | 2019-03-13 |
Family
ID=41718325
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2009/0461A JO3382B1 (ar) | 2008-12-23 | 2009-12-02 | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
JOP/2019/0017A JOP20190017B1 (ar) | 2008-12-23 | 2019-02-07 | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2019/0017A JOP20190017B1 (ar) | 2008-12-23 | 2019-02-07 | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
Country Status (40)
Country | Link |
---|---|
US (6) | US9102731B2 (ar) |
EP (3) | EP2379594B8 (ar) |
JP (6) | JP5761805B2 (ar) |
KR (4) | KR101740615B1 (ar) |
CN (2) | CN102348722B (ar) |
AR (1) | AR074857A1 (ar) |
AU (2) | AU2009330175C1 (ar) |
BR (2) | BR122020010360B1 (ar) |
CA (1) | CA2746858C (ar) |
CL (1) | CL2011001578A1 (ar) |
CO (1) | CO6400232A2 (ar) |
CR (1) | CR20110400A (ar) |
CY (3) | CY1119465T1 (ar) |
DK (2) | DK3184546T3 (ar) |
EA (2) | EA201891500A3 (ar) |
ES (2) | ES2643835T3 (ar) |
HR (2) | HRP20171690T1 (ar) |
HU (3) | HUE045966T2 (ar) |
IL (2) | IL213429A (ar) |
JO (2) | JO3382B1 (ar) |
LT (3) | LT3184546T (ar) |
LU (1) | LUC00095I2 (ar) |
MA (1) | MA32982B1 (ar) |
ME (1) | ME03601B (ar) |
MX (1) | MX2011006804A (ar) |
MY (1) | MY180564A (ar) |
NL (1) | NL300961I2 (ar) |
NO (2) | NO2379594T3 (ar) |
NZ (2) | NZ623541A (ar) |
PE (1) | PE20120427A1 (ar) |
PL (2) | PL2379594T3 (ar) |
PT (2) | PT2379594T (ar) |
RS (2) | RS56567B1 (ar) |
SG (2) | SG172307A1 (ar) |
SI (2) | SI3184546T1 (ar) |
TN (1) | TN2011000283A1 (ar) |
TW (4) | TWI574697B (ar) |
UA (1) | UA108066C2 (ar) |
WO (1) | WO2010075238A1 (ar) |
ZA (1) | ZA201105418B (ar) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
BRPI0820387A2 (pt) * | 2007-11-21 | 2015-05-26 | Amgen Inc | Agentes de ligação de wise e epítopos |
MX2010009722A (es) | 2008-03-04 | 2010-09-30 | Pfizer Ltd | Procedimiento de tratamiento del dolor cronico. |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
EP3165236B1 (en) | 2009-08-28 | 2022-03-16 | Teva Pharmaceuticals International GmbH | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
KR101965461B1 (ko) | 2011-05-20 | 2019-04-04 | 앨더바이오 홀딩스 엘엘씨 | 필요한 대상체, 특히 편두통 환자의 광선공포증 또는 광선 혐오증을 예방 또는 억제하기 위한 항-cgrp 항체 및 항체 단편의 용도 |
LT3495392T (lt) | 2011-05-20 | 2021-09-27 | H. Lundbeck A/S | Anti-cgrp kompozicijos ir jų panaudojimas |
NZ732875A (en) | 2011-05-20 | 2022-08-26 | H Lundbeck As | Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
WO2014144632A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Human pac1 antibodies |
WO2014151834A2 (en) * | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
CN105637097A (zh) | 2013-08-05 | 2016-06-01 | 特韦斯特生物科学公司 | 从头合成的基因文库 |
CN105873626A (zh) | 2013-10-24 | 2016-08-17 | 美国安进公司 | 注射器和组装方法 |
US10758683B2 (en) | 2013-10-24 | 2020-09-01 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
JP6568099B2 (ja) | 2014-03-21 | 2019-08-28 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH | カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
JP6640113B2 (ja) | 2014-05-07 | 2020-02-05 | アムジエン・インコーポレーテツド | 衝撃低減要素を有する自動注入器 |
CA2949846C (en) | 2014-06-03 | 2023-09-05 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
AR101875A1 (es) * | 2014-09-15 | 2017-01-18 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas |
MX2021014323A (es) | 2014-10-14 | 2023-02-02 | Amgen Inc | Dispositivo de inyección de fármaco con indicadores visuales y audibles. |
WO2016100781A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with proximity sensor |
US11357916B2 (en) | 2014-12-19 | 2022-06-14 | Amgen Inc. | Drug delivery device with live button or user interface field |
KR20170128234A (ko) | 2015-01-16 | 2017-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ror1에 특이적인 항체 및 키메라 항원 수용체 |
WO2016126882A1 (en) | 2015-02-04 | 2016-08-11 | Twist Bioscience Corporation | Methods and devices for de novo oligonucleic acid assembly |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
WO2016172377A1 (en) | 2015-04-21 | 2016-10-27 | Twist Bioscience Corporation | Devices and methods for oligonucleic acid library synthesis |
JOP20200116A1 (ar) * | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
US10464983B2 (en) | 2015-05-13 | 2019-11-05 | The Board Of Regents Of The University Of Oklahoma | Variants of adrenomedullin and calcitonin gene-related peptide and methods of use |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
US10844373B2 (en) | 2015-09-18 | 2020-11-24 | Twist Bioscience Corporation | Oligonucleic acid variant libraries and synthesis thereof |
CN108698012A (zh) | 2015-09-22 | 2018-10-23 | 特韦斯特生物科学公司 | 用于核酸合成的柔性基底 |
JP7082568B2 (ja) | 2015-12-09 | 2022-06-08 | アムジエン・インコーポレーテツド | 信号伝達キャップ付き自動注射器 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
JP7029401B2 (ja) | 2016-02-02 | 2022-03-03 | フレッド ハッチンソン キャンサー リサーチ センター | 抗ror1抗体およびその使用 |
WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
CN109311977B (zh) | 2016-04-15 | 2022-06-14 | H.伦德贝克公司 | 人源化的抗pacap抗体及其用途 |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
JP7309363B2 (ja) | 2016-05-13 | 2023-07-18 | アムジエン・インコーポレーテツド | バイアル・スリーブ組立体 |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
EP3465124A1 (en) | 2016-06-03 | 2019-04-10 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
US11285266B2 (en) | 2016-07-01 | 2022-03-29 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
KR102217487B1 (ko) | 2016-09-21 | 2021-02-23 | 트위스트 바이오사이언스 코포레이션 | 핵산 기반 데이터 저장 |
EP3515488A1 (en) | 2016-09-23 | 2019-07-31 | Teva Pharmaceuticals International GmbH | Treating cluster headache |
BR112019005823A2 (pt) | 2016-09-23 | 2019-06-25 | Teva Pharmaceuticals Int Gmbh | tratamento para enxaqueca refratária |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
US11993645B2 (en) | 2017-01-11 | 2024-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising R-Spondin (RSPO) surrogate molecules |
JP2020503976A (ja) | 2017-01-17 | 2020-02-06 | アムジエン・インコーポレーテツド | 注入デバイスならびに関連する使用および組立方法 |
JP7305543B2 (ja) | 2017-01-26 | 2023-07-10 | スロゼン オペレーティング, インコーポレイテッド | 組織特異的Wntシグナル増強分子およびその使用 |
JP7280189B2 (ja) | 2017-02-17 | 2023-05-23 | アムジエン・インコーポレーテツド | 薬物送達装置用の挿入機構 |
WO2018151890A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
SG11201907713WA (en) | 2017-02-22 | 2019-09-27 | Twist Bioscience Corp | Nucleic acid based data storage |
JP7195262B2 (ja) | 2017-03-02 | 2022-12-23 | ベス イスラエル デアコネス メディカル センター インコーポレイティッド | カルシトニン遺伝子関連ペプチドを指向する抗体に応答性の頭痛患者の選択方法 |
CA3050927A1 (en) | 2017-03-06 | 2018-09-13 | Brian Stonecipher | Drug delivery device with activation prevention feature |
US11571511B2 (en) | 2017-03-07 | 2023-02-07 | Amgen Inc. | Insertion mechanism and method of inserting a needle of a drug delivery device |
WO2018165499A1 (en) | 2017-03-09 | 2018-09-13 | Amgen Inc. | Insertion mechanism for drug delivery device |
CA3052676A1 (en) | 2017-03-28 | 2018-10-04 | Amgen Inc. | Plunger rod and syringe assembly system and method |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
MA49447A (fr) | 2017-06-22 | 2020-04-29 | Amgen Inc | Réduction des impacts/chocs d'activation d'un dispositif |
EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
WO2019014014A1 (en) | 2017-07-14 | 2019-01-17 | Amgen Inc. | NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM |
MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
MA49676A (fr) | 2017-07-25 | 2020-06-03 | Amgen Inc | Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé |
JP2020528296A (ja) | 2017-07-25 | 2020-09-24 | アムジエン・インコーポレーテツド | ギヤモジュールを有する薬物送達デバイス及び関連する組立方法 |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
IL272636B1 (en) | 2017-10-06 | 2024-06-01 | Amgen Inc | Drug delivery device with combination assembly and related assembly method |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
JP7066840B2 (ja) | 2017-10-20 | 2022-05-13 | ツイスト バイオサイエンス コーポレーション | ポリヌクレオチド合成のための加熱されたナノウェル |
US11826480B2 (en) | 2017-11-03 | 2023-11-28 | Amgen Inc. | Systems and approaches for sterilizing a drug delivery device |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
CA3079197A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
CN116832271A (zh) | 2017-11-10 | 2023-10-03 | 安进公司 | 用于药物递送装置的柱塞 |
CA3079540A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Door latch mechanism for drug delivery device |
CA3087951A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Pac1 antibodies and uses thereof |
AR114722A1 (es) | 2018-04-02 | 2020-10-07 | Amgen Inc | Composiciones de erenumab y usos de las mismas |
AU2019250882A1 (en) | 2018-04-12 | 2020-11-05 | Amgen Inc. | Methods for making stable protein compositions |
KR20210013128A (ko) | 2018-05-18 | 2021-02-03 | 트위스트 바이오사이언스 코포레이션 | 핵산 하이브리드화를 위한 폴리뉴클레오타이드, 시약 및 방법 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
CN112469454B (zh) | 2018-07-24 | 2024-01-26 | 安进公司 | 用于施用药物的输送装置 |
EP3826699A1 (en) | 2018-07-24 | 2021-06-02 | Amgen Inc. | Delivery devices for administering drugs |
EP3829692A1 (en) | 2018-07-31 | 2021-06-09 | Amgen Inc. | Fluid path assembly for a drug delivery device |
MA53724A (fr) | 2018-09-24 | 2021-12-29 | Amgen Inc | Systèmes et procédés de dosage interventionnel |
WO2020068476A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
CN112805048B (zh) | 2018-10-02 | 2023-09-22 | 安进公司 | 具有内部力传递的用于药物递送的注射系统 |
AR116607A1 (es) | 2018-10-05 | 2021-05-26 | Amgen Inc | Dispositivo de administración de fármacos con indicador de dosis |
AR116704A1 (es) | 2018-10-15 | 2021-06-02 | Amgen Inc | Dispositivo de administración de fármacos con mecanismo de amortiguación |
SG11202101824VA (en) | 2018-10-15 | 2021-03-30 | Amgen Inc | Platform assembly process for drug delivery device |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
MA54057A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
WO2020146527A1 (en) | 2019-01-08 | 2020-07-16 | Alder Biopharmaceuticals, Inc. | Acute treatment and rapid treatment of headache using anti-cgrp antibodies |
CN113766930A (zh) * | 2019-02-26 | 2021-12-07 | 特韦斯特生物科学公司 | Glp1受体的变异核酸文库 |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
WO2020239014A1 (zh) * | 2019-05-30 | 2020-12-03 | 山东博安生物技术有限公司 | 抗cgrp抗体及其应用 |
CA3143524A1 (en) | 2019-06-28 | 2020-12-30 | Amgen Inc. | Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins |
CA3148261A1 (en) | 2019-08-23 | 2021-03-04 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
US20240139171A1 (en) | 2021-03-02 | 2024-05-02 | Cgrp Diagnostics Gmbh | Treatment and/or reduction of occurrence of migraine |
WO2022246055A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
WO2023215829A1 (en) * | 2022-05-05 | 2023-11-09 | Amgen Inc. | Heteromultimer binding dll3 and cd3 |
WO2024102742A1 (en) | 2022-11-07 | 2024-05-16 | Amgen Inc. | Methods for treating obesity |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
JPH02229119A (ja) | 1989-02-28 | 1990-09-11 | Toyo Jozo Co Ltd | 動脈硬化予防および治療剤 |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
AU633698B2 (en) | 1990-01-12 | 1993-02-04 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2105984C (en) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Cloning and expression of renilla luciferase |
JPH06508035A (ja) | 1991-06-14 | 1994-09-14 | ディーエヌエックス コーポレーション | トランスジェニックブタにおけるヒトヘモグロビンの生産 |
EP0593592B1 (en) | 1991-07-08 | 1998-03-25 | The University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
US5866124A (en) * | 1992-03-17 | 1999-02-02 | Novartis Corporation | Antiidiotypic antibodies for high molecular weight-melanoma associated antigen |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
DK0672141T3 (da) | 1992-10-23 | 2003-06-10 | Immunex Corp | Fremgangsmåder til fremstilling af opløselige, oligomere proteiner |
US5766880A (en) * | 1992-10-27 | 1998-06-16 | Queen's University At Kingston | Isolated nucleic acid molecules encoding multidrug resistance proteins |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
WO1995007463A1 (en) | 1993-09-10 | 1995-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of green fluorescent protein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
WO1996003993A2 (en) | 1994-08-05 | 1996-02-15 | The Rockefeller University | Modulation of thymocyte and t cell functional activity |
JPH10504457A (ja) | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | カルシトニンレセプター |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
AU741076B2 (en) | 1996-12-12 | 2001-11-22 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
DE19732944A1 (de) | 1997-07-31 | 1999-02-04 | Thomae Gmbh Dr K | Peptidische CGRP-Antagonisten |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
EP1064360B1 (en) | 1998-03-27 | 2008-03-05 | Prolume, Ltd. | Luciferases, gfp fluorescent proteins, their nucleic acids and the use thereof in diagnostics |
US6268474B1 (en) | 1998-04-30 | 2001-07-31 | Creighton University | Peptide antagonists of CGRP-receptor superfamily and methods of use |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
EP1234174A1 (en) * | 1999-12-02 | 2002-08-28 | Myriad Genetics, Inc. | Protein-protein interactions |
US20020090646A1 (en) | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
FR2821080B1 (fr) | 2001-02-20 | 2003-12-19 | Sanofi Synthelabo | Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques |
JP2005500034A (ja) * | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
EP1438325B1 (en) | 2001-09-27 | 2009-12-30 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
US7658924B2 (en) | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
PT1576112E (pt) * | 2002-01-18 | 2012-05-25 | Zymogenetics Inc | Multímeros de receptor de citocina zcytor17 |
US20040110170A1 (en) | 2002-05-18 | 2004-06-10 | The Regents Of The University Of California | Cloning and characterization of calcitonin gene related peptide receptors |
US20070071744A1 (en) * | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
EP1556020B1 (en) * | 2002-08-12 | 2009-02-25 | Actavis Group hf. | Use of cgrp antagonist compounds for treatment of psoriasis |
US20040176577A1 (en) * | 2002-09-10 | 2004-09-09 | Eva Rojer | Immunoassays for specific determination of SCCA isoforms |
WO2004097421A2 (en) | 2003-04-29 | 2004-11-11 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl) |
NZ548978A (en) * | 2004-02-11 | 2009-10-30 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
US7423128B2 (en) * | 2004-11-03 | 2008-09-09 | Amgen Fremont Inc. | Anti-properdin antibodies, and methods for making and using same |
WO2006068953A2 (en) * | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
EP1900374B1 (en) | 2005-06-16 | 2014-03-12 | Takayuki Shindo | Angiogenetic agent containing adrenomedulin as the active ingredient |
GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
RS57194B1 (sr) | 2005-11-14 | 2018-07-31 | Teva Pharmaceuticals Int Gmbh | Antagonistička antitela specifična za peptid koji je u vezi sa genom za kalcitonin za lečenje klaster glavobolje |
WO2007076336A1 (en) * | 2005-12-22 | 2007-07-05 | Eli Lilly And Company | Treatment of migraine with anti-cgrp antibodies |
TW200815474A (en) | 2006-08-03 | 2008-04-01 | Astrazeneca Ab | Antibodies alphaVbeta6 and uses thereof |
GB0708002D0 (en) | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
EP2265288B1 (en) | 2008-03-04 | 2016-05-11 | Labrys Biologics Inc. | Methods of treating inflammatory pain |
FR2934597B1 (fr) * | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
JO3382B1 (ar) * | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
EP3165236B1 (en) | 2009-08-28 | 2022-03-16 | Teva Pharmaceuticals International GmbH | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
US9401875B2 (en) | 2012-06-01 | 2016-07-26 | Nippon Telegraph And Telephone Corporation | Packet transfer processing method and packet transfer processing device |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
AR101875A1 (es) * | 2014-09-15 | 2017-01-18 | Amgen Inc | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp / receptor pac1 y usos de las mismas |
JOP20200116A1 (ar) * | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
US11385238B2 (en) * | 2017-06-30 | 2022-07-12 | Amgen Inc. | Methods of protein clips recovery |
AR114722A1 (es) * | 2018-04-02 | 2020-10-07 | Amgen Inc | Composiciones de erenumab y usos de las mismas |
-
2009
- 2009-12-02 JO JOP/2009/0461A patent/JO3382B1/ar active
- 2009-12-18 EA EA201891500A patent/EA201891500A3/ru unknown
- 2009-12-18 MY MYPI2011002908A patent/MY180564A/en unknown
- 2009-12-18 UA UAA201109219A patent/UA108066C2/ru unknown
- 2009-12-18 ME MEP-2019-240A patent/ME03601B/me unknown
- 2009-12-18 MX MX2011006804A patent/MX2011006804A/es active IP Right Grant
- 2009-12-18 HU HUE16199717A patent/HUE045966T2/hu unknown
- 2009-12-18 NZ NZ623541A patent/NZ623541A/en unknown
- 2009-12-18 LT LTEP16199717.6T patent/LT3184546T/lt unknown
- 2009-12-18 EP EP09775072.3A patent/EP2379594B8/en active Active
- 2009-12-18 CN CN200980157606.3A patent/CN102348722B/zh active Active
- 2009-12-18 NZ NZ606090A patent/NZ606090A/en unknown
- 2009-12-18 DK DK16199717.6T patent/DK3184546T3/da active
- 2009-12-18 CN CN201610333096.2A patent/CN106084045B/zh active Active
- 2009-12-18 ES ES09775072.3T patent/ES2643835T3/es active Active
- 2009-12-18 EP EP19181187.6A patent/EP3569620A1/en active Pending
- 2009-12-18 EA EA201100892A patent/EA031320B1/ru active Protection Beyond IP Right Term
- 2009-12-18 AU AU2009330175A patent/AU2009330175C1/en active Active
- 2009-12-18 NO NO09775072A patent/NO2379594T3/no unknown
- 2009-12-18 KR KR1020117017235A patent/KR101740615B1/ko active IP Right Grant
- 2009-12-18 DK DK09775072.3T patent/DK2379594T3/en active
- 2009-12-18 PE PE2011001269A patent/PE20120427A1/es active IP Right Grant
- 2009-12-18 BR BR122020010360-4A patent/BR122020010360B1/pt active IP Right Grant
- 2009-12-18 PT PT97750723T patent/PT2379594T/pt unknown
- 2009-12-18 KR KR1020187011418A patent/KR20180043850A/ko active Application Filing
- 2009-12-18 EP EP16199717.6A patent/EP3184546B8/en active Active
- 2009-12-18 SG SG2011045556A patent/SG172307A1/en unknown
- 2009-12-18 JP JP2011543606A patent/JP5761805B2/ja active Active
- 2009-12-18 ES ES16199717T patent/ES2746571T3/es active Active
- 2009-12-18 HU HUE09775072A patent/HUE034506T2/en unknown
- 2009-12-18 KR KR1020177013822A patent/KR101853393B1/ko active IP Right Grant
- 2009-12-18 BR BRPI0922505-6A patent/BRPI0922505B1/pt active IP Right Grant
- 2009-12-18 KR KR1020197013698A patent/KR20190054181A/ko not_active Application Discontinuation
- 2009-12-18 PL PL09775072T patent/PL2379594T3/pl unknown
- 2009-12-18 SI SI200931989T patent/SI3184546T1/sl unknown
- 2009-12-18 WO PCT/US2009/068858 patent/WO2010075238A1/en active Application Filing
- 2009-12-18 PL PL16199717T patent/PL3184546T3/pl unknown
- 2009-12-18 RS RS20171121A patent/RS56567B1/sr unknown
- 2009-12-18 SI SI200931756T patent/SI2379594T1/sl unknown
- 2009-12-18 LT LTEP09775072.3T patent/LT2379594T/lt unknown
- 2009-12-18 CA CA2746858A patent/CA2746858C/en active Active
- 2009-12-18 US US12/642,711 patent/US9102731B2/en active Active
- 2009-12-18 RS RSP20191122 patent/RS59343B1/sr unknown
- 2009-12-18 SG SG10201401879TA patent/SG10201401879TA/en unknown
- 2009-12-18 MA MA34035A patent/MA32982B1/ar unknown
- 2009-12-18 PT PT16199717T patent/PT3184546T/pt unknown
- 2009-12-22 TW TW098144377A patent/TWI574697B/zh active
- 2009-12-22 TW TW108136419A patent/TWI754176B/zh active
- 2009-12-22 TW TW105134382A patent/TWI688403B/zh active
- 2009-12-22 TW TW110149087A patent/TW202241950A/zh unknown
- 2009-12-22 AR ARP090105053A patent/AR074857A1/es active IP Right Grant
-
2011
- 2011-06-01 TN TN2011000283A patent/TN2011000283A1/fr unknown
- 2011-06-06 IL IL213429A patent/IL213429A/en active Protection Beyond IP Right Term
- 2011-06-23 CL CL2011001578A patent/CL2011001578A1/es unknown
- 2011-07-15 CO CO11088995A patent/CO6400232A2/es active IP Right Grant
- 2011-07-22 ZA ZA2011/05418A patent/ZA201105418B/en unknown
- 2011-07-22 CR CR20110400A patent/CR20110400A/es unknown
-
2012
- 2012-09-12 US US13/612,615 patent/US20130071410A1/en not_active Abandoned
-
2013
- 2013-04-10 AU AU2013205271A patent/AU2013205271C1/en active Active
-
2014
- 2014-08-12 JP JP2014164088A patent/JP6261132B2/ja active Active
-
2015
- 2015-06-26 US US14/752,493 patent/US9862771B2/en active Active
- 2015-11-09 JP JP2015219157A patent/JP2016026224A/ja not_active Withdrawn
-
2016
- 2016-01-26 IL IL243784A patent/IL243784A/en active IP Right Grant
-
2017
- 2017-08-28 CY CY20171100901T patent/CY1119465T1/el unknown
- 2017-11-06 HR HRP20171690TT patent/HRP20171690T1/hr unknown
- 2017-11-28 US US15/824,827 patent/US20180142029A1/en not_active Abandoned
-
2018
- 2018-12-04 CY CY2018032C patent/CY2018032I1/el unknown
- 2018-12-10 HU HUS1800047C patent/HUS1800047I1/hu unknown
- 2018-12-12 NL NL300961C patent/NL300961I2/nl unknown
- 2018-12-14 LT LTPA2018017C patent/LTC2379594I2/lt unknown
- 2018-12-17 NO NO2018042C patent/NO2018042I1/no unknown
- 2018-12-20 LU LU00095C patent/LUC00095I2/fr unknown
- 2018-12-28 JP JP2018246704A patent/JP2019062907A/ja not_active Withdrawn
-
2019
- 2019-02-07 JO JOP/2019/0017A patent/JOP20190017B1/ar active
- 2019-07-25 HR HRP20191341TT patent/HRP20191341T8/hr unknown
- 2019-09-19 CY CY20191100989T patent/CY1122658T1/el unknown
-
2020
- 2020-11-27 JP JP2020196689A patent/JP2021036912A/ja active Pending
- 2020-12-03 US US17/111,442 patent/US20210179722A1/en active Pending
- 2020-12-03 US US17/111,453 patent/US20210179723A1/en active Pending
-
2023
- 2023-06-21 JP JP2023101810A patent/JP2023116783A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20190017B1 (ar) | أجسام مضادة ترتبط مع مستقبل cgrp بشري | |
MX351502B (es) | Anticuerpos de union de albumina y fragmentos de union de los mismos. | |
TN2012000167A1 (en) | Human il-23 antigen binding proteins | |
PH12014502527B1 (en) | St2 antigen binding proteins | |
EA201001223A1 (ru) | Стабилизированные белковые композиции | |
NZ583282A (en) | Human c-fms antigen binding proteins | |
MX2012012927A (es) | Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6). | |
MY150400A (en) | Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof | |
WO2010019570A3 (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
NZ601615A (en) | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor | |
MY160590A (en) | Cd127 binding proteins | |
NZ593905A (en) | Il-1 binding proteins | |
GEP20146112B (en) | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and usage thereof | |
MX2009013824A (es) | Proteinas de enlace de antigeno que enlazan par-2. | |
WO2008151819A3 (en) | Treatment of tumors using specific anti-l1 antibody | |
EA201290630A1 (ru) | Лечение расстройства обмена веществ | |
UA100531C2 (ru) | Антитело, которое специфически связывается с тимическим стромальным лимфопоэтином (tslp) |